Getting Medicaid to cover Wegovy is difficult because federal law allows states to exclude weight loss drugs from coverage, and most states do exactly that. As of January 2026, only 13 state Medicaid programs cover GLP-1 medications like Wegovy for obesity treatment under their fee-for-service plans. Your path to coverage depends on which state you live in, why your doctor is prescribing it, and whether you qualify through a non-obesity indication.
Why Most State Medicaid Programs Don’t Cover Wegovy
Medicaid programs are normally required to cover nearly all FDA-approved drugs from participating manufacturers. But federal law carves out a specific exception for “agents used for anorexia, weight loss, or weight gain.” Because Wegovy’s original approval was for chronic weight management, it falls into this exclusion, and states can choose not to pay for it.
This makes Wegovy fundamentally different from drugs like insulin or blood pressure medications, which Medicaid must cover. Each state decides independently whether to include weight loss drugs in its formulary, and 37 states have opted not to. If your state doesn’t cover obesity medications, no amount of documentation from your doctor will change that for the weight loss indication alone. You’ll need to explore alternative pathways.
The Cardiovascular Loophole That Changes Everything
Here’s the key detail most people miss: since March 2024, Wegovy has a separate FDA approval to reduce the risk of heart attack, stroke, and cardiovascular death in adults with established heart disease and obesity or overweight. This is not a weight loss indication. It’s a cardiovascular one. And because Medicaid is required to cover drugs for their approved medical indications (outside the weight loss exclusion), states must cover Wegovy when it’s prescribed for cardiovascular risk reduction.
To qualify under this pathway, you typically need to be 45 or older, have a BMI of 27 or higher, and have a documented history of heart attack, stroke, or symptomatic peripheral arterial disease. Maryland’s Medicaid program, for example, requires the prescription to come from or in consultation with a cardiologist. If you have heart disease and meet these criteria, this is your strongest route to coverage regardless of which state you live in.
Check Your State’s Coverage First
Before anything else, find out whether your state is one of the 13 that covers GLP-1 drugs for obesity. You can call the member services number on your Medicaid card or check your state Medicaid agency’s website for its preferred drug list (also called a formulary). If you’re enrolled through a managed care organization rather than fee-for-service Medicaid, your plan may have its own formulary that differs from the state’s baseline policy, so check with your specific plan.
If your state does cover Wegovy for weight management, you’ll still need prior authorization. Coverage doesn’t mean automatic approval.
What Prior Authorization Requires
Every state that covers Wegovy puts it behind a prior authorization wall, meaning your doctor must submit paperwork proving you meet specific clinical criteria before the pharmacy can fill the prescription. The exact requirements vary by state, but North Carolina’s criteria are a good example of what to expect.
For adults, you generally need one of the following:
- BMI of 30 or higher, with no additional conditions required
- BMI of 27 or higher plus at least one weight-related health problem such as high blood pressure, type 2 diabetes, obstructive sleep apnea, heart disease, or high cholesterol
For adolescents aged 12 to 17, the thresholds are based on BMI percentiles for age and sex, with the 95th percentile (or a BMI of 30 or above) typically qualifying on its own, and the 85th percentile qualifying when paired with a severe weight-related condition.
Beyond the BMI numbers, states commonly require that your doctor document a baseline weight and BMI measured within the past 45 to 90 days, that you are actively participating in lifestyle changes like a structured diet and physical activity plan, and that you are not taking another GLP-1 medication at the same time. Some states, like Maryland, go further and require attestation that you tried weight loss management in the past six months and didn’t achieve results. Your doctor needs to keep supporting medical records on file.
How to Build the Strongest Case
Prior authorization denials often come down to incomplete paperwork, not ineligibility. A few practical steps improve your odds significantly.
First, schedule a dedicated appointment with your doctor specifically to discuss Wegovy and document everything the state requires. Bring up every weight-related condition you have, even ones you haven’t discussed before, because conditions like sleep apnea or high cholesterol can make the difference between a BMI-27 denial and a BMI-27 approval. Make sure a recent weight and BMI measurement are recorded in your chart, ideally within the past 45 days.
Second, ask your doctor’s office whether they have experience submitting prior authorizations for GLP-1 medications. Offices that routinely handle these requests know which boxes the state reviewers look for. If your doctor is unfamiliar with the process, they can download your state’s specific prior authorization form from the Medicaid agency website. These forms spell out exactly what clinical documentation to submit.
Third, if your state requires a trial of lifestyle modifications before approval, document that effort. This could mean a referral to a dietitian, enrollment in a weight management program, or even a few months of recorded diet and exercise efforts in your medical chart. Maryland requires six months of documented weight loss attempts. North Carolina requires that you be currently engaged in lifestyle changes. Knowing your state’s specific timeline prevents a denial for something easily fixable.
What to Do If You’re Denied
A denial isn’t the end. Medicaid enrollees have the right to appeal through a process called a fair hearing, which is an administrative review where you can challenge the state’s decision. Your denial notice must include written instructions on how to request one.
The timeline for requesting a hearing varies by state, ranging from 30 to 90 days from the date on your denial notice. If you already had Medicaid benefits and request a hearing before the effective date of the denial (sometimes as few as 10 days after the notice is mailed), the state must continue your existing benefits until a decision is reached. Once a hearing is granted, the state generally has 90 days to issue a final decision.
If the decision goes in your favor, the state must implement it retroactively to the date of the original denial. If it doesn’t, the written decision will explain any additional appeal options, which may include judicial review.
For the hearing itself, the most useful thing you can bring is documentation that you met all the clinical criteria at the time of the request. If the denial was based on missing information, your doctor can submit additional records. If it was based on a clinical judgment call, a letter from your doctor explaining the medical necessity of Wegovy specifically, rather than alternative treatments, strengthens your case.
If Your State Doesn’t Cover Weight Loss Drugs
When your state excludes obesity medications entirely, your options narrow but don’t disappear. The cardiovascular indication described above is one route. If you don’t have heart disease, talk to your doctor about whether Wegovy might be medically appropriate for another covered condition. The FDA has approved Wegovy’s active ingredient for type 2 diabetes under a different brand name, and some states are beginning to recognize overlapping benefits.
A proposed federal rule has attempted to reinterpret the statutory exclusion so that drugs “used to treat beneficiaries with obesity” would no longer be excludable, which would require all state Medicaid programs to cover them. If finalized, this change could open access for an estimated 4 million adult Medicaid enrollees. But as of early 2025, the rule has not been implemented, and the political landscape around it remains uncertain.
In the meantime, Novo Nordisk (Wegovy’s manufacturer) offers patient assistance programs that may help with costs if you don’t have coverage. Your doctor’s office or a patient advocate at your local clinic can help you explore these options alongside any state-specific assistance programs.